| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endoscopic Mucosal Resection | 34 | 2025 | 83 | 13.000 |
Why?
|
| Colonoscopy | 17 | 2025 | 247 | 4.580 |
Why?
|
| Colonic Polyps | 10 | 2025 | 86 | 3.450 |
Why?
|
| Adenoma | 7 | 2025 | 146 | 3.450 |
Why?
|
| Colorectal Neoplasms | 14 | 2025 | 639 | 3.290 |
Why?
|
| Esophageal Neoplasms | 11 | 2025 | 394 | 3.050 |
Why?
|
| Exocrine Pancreatic Insufficiency | 5 | 2025 | 40 | 2.800 |
Why?
|
| Pancreatic Neoplasms | 12 | 2025 | 743 | 2.740 |
Why?
|
| Stomach Neoplasms | 11 | 2024 | 580 | 2.590 |
Why?
|
| Colonic Neoplasms | 5 | 2025 | 265 | 2.510 |
Why?
|
| Adenocarcinoma | 11 | 2024 | 998 | 2.420 |
Why?
|
| Natural Orifice Endoscopic Surgery | 7 | 2025 | 83 | 2.410 |
Why?
|
| Suture Techniques | 3 | 2025 | 180 | 2.330 |
Why?
|
| Pancreas | 8 | 2025 | 228 | 2.220 |
Why?
|
| Myotomy | 8 | 2025 | 22 | 2.190 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 8 | 2024 | 75 | 2.130 |
Why?
|
| Pancreatitis, Chronic | 6 | 2024 | 84 | 2.110 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 5 | 2025 | 40 | 2.090 |
Why?
|
| Esophagoscopy | 8 | 2025 | 177 | 1.970 |
Why?
|
| Neuroendocrine Tumors | 2 | 2025 | 70 | 1.730 |
Why?
|
| Endosonography | 8 | 2025 | 79 | 1.700 |
Why?
|
| Gastrointestinal Neoplasms | 7 | 2024 | 85 | 1.650 |
Why?
|
| Endoscopy, Gastrointestinal | 9 | 2024 | 231 | 1.610 |
Why?
|
| Esophageal Achalasia | 4 | 2025 | 48 | 1.500 |
Why?
|
| Forkhead Transcription Factors | 2 | 2026 | 372 | 1.490 |
Why?
|
| Pancreatic Diseases | 4 | 2025 | 42 | 1.480 |
Why?
|
| Barrett Esophagus | 5 | 2024 | 359 | 1.460 |
Why?
|
| Pancreatitis | 5 | 2021 | 142 | 1.460 |
Why?
|
| Pancreatic Cyst | 4 | 2021 | 29 | 1.450 |
Why?
|
| MicroRNAs | 5 | 2026 | 899 | 1.430 |
Why?
|
| Gastrectomy | 5 | 2020 | 107 | 1.400 |
Why?
|
| Treatment Outcome | 37 | 2025 | 13025 | 1.360 |
Why?
|
| Flavonoids | 2 | 2022 | 83 | 1.350 |
Why?
|
| Humans | 119 | 2026 | 132041 | 1.310 |
Why?
|
| Operative Time | 5 | 2025 | 205 | 1.310 |
Why?
|
| Early Detection of Cancer | 7 | 2025 | 418 | 1.300 |
Why?
|
| Middle Aged | 46 | 2025 | 28946 | 1.240 |
Why?
|
| Aged | 38 | 2025 | 21288 | 1.230 |
Why?
|
| Artificial Intelligence | 2 | 2025 | 328 | 1.200 |
Why?
|
| Carcinoma, Pancreatic Ductal | 2 | 2025 | 187 | 1.180 |
Why?
|
| Gastric Mucosa | 5 | 2024 | 492 | 1.180 |
Why?
|
| Retrospective Studies | 36 | 2025 | 17748 | 1.120 |
Why?
|
| Gastroenterology | 4 | 2025 | 221 | 1.090 |
Why?
|
| Esophageal Sphincter, Lower | 3 | 2025 | 16 | 1.030 |
Why?
|
| Neoplasm, Residual | 2 | 2025 | 137 | 1.030 |
Why?
|
| Male | 59 | 2025 | 65425 | 0.990 |
Why?
|
| Endoscopy, Digestive System | 5 | 2024 | 154 | 0.980 |
Why?
|
| Female | 57 | 2026 | 71380 | 0.950 |
Why?
|
| Duodenoscopy | 1 | 2025 | 17 | 0.930 |
Why?
|
| Duodenal Neoplasms | 1 | 2025 | 28 | 0.910 |
Why?
|
| Bile Duct Neoplasms | 2 | 2021 | 131 | 0.900 |
Why?
|
| Wound Closure Techniques | 1 | 2025 | 27 | 0.900 |
Why?
|
| Breast Neoplasms | 4 | 2026 | 2657 | 0.870 |
Why?
|
| Postoperative Complications | 9 | 2025 | 3133 | 0.870 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2025 | 1279 | 0.840 |
Why?
|
| Prospective Studies | 18 | 2025 | 6539 | 0.830 |
Why?
|
| Antioxidants | 4 | 2024 | 336 | 0.820 |
Why?
|
| Fundoplication | 1 | 2024 | 70 | 0.810 |
Why?
|
| Plant Extracts | 2 | 2022 | 139 | 0.800 |
Why?
|
| Colonic Diseases | 1 | 2023 | 37 | 0.790 |
Why?
|
| Trastuzumab | 1 | 2024 | 148 | 0.790 |
Why?
|
| Adipose Tissue | 1 | 2025 | 495 | 0.750 |
Why?
|
| Colon | 2 | 2022 | 361 | 0.750 |
Why?
|
| Educational Measurement | 1 | 2025 | 318 | 0.750 |
Why?
|
| Intestinal Obstruction | 1 | 2023 | 88 | 0.740 |
Why?
|
| Sutures | 2 | 2022 | 65 | 0.740 |
Why?
|
| Precancerous Conditions | 2 | 2023 | 283 | 0.740 |
Why?
|
| Ocimum basilicum | 1 | 2021 | 1 | 0.720 |
Why?
|
| Berberine | 1 | 2021 | 9 | 0.720 |
Why?
|
| Crohn Disease | 2 | 2023 | 291 | 0.720 |
Why?
|
| Selenium | 1 | 2021 | 15 | 0.720 |
Why?
|
| Gastroesophageal Reflux | 2 | 2024 | 334 | 0.700 |
Why?
|
| Intestinal Mucosa | 6 | 2023 | 765 | 0.700 |
Why?
|
| Cytodiagnosis | 1 | 2021 | 20 | 0.680 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2011 | 107 | 0.670 |
Why?
|
| Esophagectomy | 1 | 2021 | 71 | 0.670 |
Why?
|
| Hypoglycemic Agents | 2 | 2022 | 475 | 0.660 |
Why?
|
| Biopsy, Needle | 1 | 2021 | 216 | 0.650 |
Why?
|
| Liver Cirrhosis | 3 | 2024 | 905 | 0.650 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2021 | 147 | 0.650 |
Why?
|
| Aged, 80 and over | 14 | 2025 | 6930 | 0.640 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2022 | 304 | 0.630 |
Why?
|
| Biliary Tract Surgical Procedures | 2 | 2021 | 23 | 0.630 |
Why?
|
| Endoscopy | 3 | 2023 | 284 | 0.620 |
Why?
|
| Liver | 4 | 2022 | 1805 | 0.610 |
Why?
|
| Hypertriglyceridemia | 1 | 2021 | 118 | 0.610 |
Why?
|
| Gastric Stump | 1 | 2019 | 1 | 0.600 |
Why?
|
| Stents | 4 | 2023 | 781 | 0.600 |
Why?
|
| Esophageal Motility Disorders | 3 | 2025 | 21 | 0.600 |
Why?
|
| Indomethacin | 1 | 2019 | 81 | 0.590 |
Why?
|
| Catheter Ablation | 1 | 2022 | 317 | 0.590 |
Why?
|
| Microscopy, Confocal | 3 | 2019 | 363 | 0.580 |
Why?
|
| Cholangitis | 2 | 2016 | 40 | 0.560 |
Why?
|
| Nanoparticles | 1 | 2021 | 293 | 0.560 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 3095 | 0.560 |
Why?
|
| Quality Indicators, Health Care | 2 | 2019 | 237 | 0.560 |
Why?
|
| Helicobacter pylori | 3 | 2023 | 1359 | 0.560 |
Why?
|
| Neoplasm Staging | 3 | 2025 | 1333 | 0.560 |
Why?
|
| Helicobacter Infections | 3 | 2023 | 1303 | 0.560 |
Why?
|
| Pancreatic Elastase | 1 | 2018 | 12 | 0.560 |
Why?
|
| Common Bile Duct | 2 | 2015 | 16 | 0.550 |
Why?
|
| Malabsorption Syndromes | 1 | 2018 | 28 | 0.550 |
Why?
|
| Adult | 21 | 2025 | 31747 | 0.540 |
Why?
|
| Biopsy | 3 | 2024 | 1254 | 0.530 |
Why?
|
| Neoplasm Invasiveness | 4 | 2026 | 646 | 0.530 |
Why?
|
| Lymphatic Metastasis | 5 | 2025 | 433 | 0.520 |
Why?
|
| Quality of Life | 4 | 2024 | 2118 | 0.520 |
Why?
|
| Pilot Projects | 5 | 2025 | 1474 | 0.520 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 35 | 0.510 |
Why?
|
| Surgical Instruments | 3 | 2025 | 56 | 0.510 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2017 | 62 | 0.510 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 131 | 0.510 |
Why?
|
| Needles | 1 | 2017 | 52 | 0.510 |
Why?
|
| Apoptosis | 5 | 2026 | 1863 | 0.510 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 1811 | 0.490 |
Why?
|
| Intestinal Polyps | 2 | 2024 | 30 | 0.490 |
Why?
|
| Sensitivity and Specificity | 5 | 2024 | 2148 | 0.480 |
Why?
|
| Oxidative Stress | 5 | 2025 | 812 | 0.480 |
Why?
|
| Feces | 2 | 2018 | 725 | 0.480 |
Why?
|
| Dissection | 3 | 2021 | 59 | 0.480 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1621 | 0.480 |
Why?
|
| Pyloric Antrum | 1 | 2015 | 63 | 0.460 |
Why?
|
| Cystadenoma, Serous | 2 | 2025 | 16 | 0.460 |
Why?
|
| Radiography, Abdominal | 1 | 2015 | 46 | 0.460 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2015 | 39 | 0.450 |
Why?
|
| Silver | 2 | 2025 | 27 | 0.440 |
Why?
|
| Kidney | 1 | 2021 | 1303 | 0.440 |
Why?
|
| Carcinoma, Papillary | 1 | 2015 | 92 | 0.430 |
Why?
|
| Adenomatous Polyps | 1 | 2014 | 14 | 0.430 |
Why?
|
| Gastroparesis | 1 | 2015 | 69 | 0.430 |
Why?
|
| Metal Nanoparticles | 2 | 2025 | 55 | 0.430 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1306 | 0.410 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2023 | 1249 | 0.410 |
Why?
|
| Quality of Health Care | 1 | 2017 | 411 | 0.400 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 325 | 0.400 |
Why?
|
| Obesity | 1 | 2025 | 2394 | 0.390 |
Why?
|
| Metaplasia | 3 | 2022 | 216 | 0.390 |
Why?
|
| Margins of Excision | 2 | 2024 | 56 | 0.380 |
Why?
|
| Cholagogues and Choleretics | 1 | 2012 | 24 | 0.380 |
Why?
|
| Fluid Therapy | 2 | 2019 | 145 | 0.380 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2012 | 38 | 0.380 |
Why?
|
| Rats | 6 | 2023 | 3458 | 0.380 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2012 | 5 | 0.380 |
Why?
|
| Gallstones | 1 | 2012 | 18 | 0.370 |
Why?
|
| Carcinoembryonic Antigen | 1 | 2012 | 25 | 0.370 |
Why?
|
| Colic | 1 | 2012 | 9 | 0.370 |
Why?
|
| Streptozocin | 2 | 2022 | 26 | 0.360 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2012 | 75 | 0.360 |
Why?
|
| Carcinoma, Ehrlich Tumor | 2 | 2024 | 3 | 0.350 |
Why?
|
| Common Bile Duct Diseases | 1 | 2011 | 1 | 0.350 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2022 | 1420 | 0.340 |
Why?
|
| Mediastinum | 1 | 2011 | 46 | 0.340 |
Why?
|
| Bacteremia | 1 | 2015 | 429 | 0.340 |
Why?
|
| Financing, Government | 1 | 2011 | 33 | 0.340 |
Why?
|
| Research Support as Topic | 1 | 2011 | 61 | 0.330 |
Why?
|
| Feasibility Studies | 4 | 2024 | 838 | 0.330 |
Why?
|
| Birth Weight | 1 | 2012 | 347 | 0.320 |
Why?
|
| Ultrasonography, Interventional | 1 | 2011 | 206 | 0.300 |
Why?
|
| Colonoscopes | 1 | 2009 | 10 | 0.300 |
Why?
|
| Risk Factors | 8 | 2025 | 11020 | 0.280 |
Why?
|
| Tumor Burden | 3 | 2017 | 241 | 0.280 |
Why?
|
| Models, Statistical | 2 | 2025 | 494 | 0.280 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2023 | 87 | 0.270 |
Why?
|
| Intubation, Gastrointestinal | 2 | 2018 | 52 | 0.270 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 330 | 0.260 |
Why?
|
| MCF-7 Cells | 2 | 2026 | 209 | 0.260 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 547 | 0.260 |
Why?
|
| Blood Glucose | 2 | 2022 | 1105 | 0.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2026 | 2020 | 0.260 |
Why?
|
| Animals | 11 | 2026 | 34262 | 0.260 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 406 | 0.250 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2011 | 328 | 0.250 |
Why?
|
| Propensity Score | 2 | 2025 | 268 | 0.240 |
Why?
|
| Paclitaxel | 2 | 2024 | 134 | 0.240 |
Why?
|
| Formaldehyde | 1 | 2025 | 50 | 0.230 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3457 | 0.230 |
Why?
|
| Biostatistics | 1 | 2025 | 14 | 0.230 |
Why?
|
| Specialty Boards | 1 | 2025 | 25 | 0.220 |
Why?
|
| Colectomy | 1 | 2025 | 88 | 0.220 |
Why?
|
| Caffeine | 1 | 2025 | 67 | 0.220 |
Why?
|
| Risk Assessment | 3 | 2024 | 3718 | 0.220 |
Why?
|
| Duodenum | 1 | 2025 | 112 | 0.220 |
Why?
|
| Biomedical Research | 1 | 2011 | 559 | 0.220 |
Why?
|
| Cell Proliferation | 2 | 2026 | 2477 | 0.220 |
Why?
|
| Electrosurgery | 1 | 2024 | 17 | 0.210 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2026 | 259 | 0.210 |
Why?
|
| Gels | 1 | 2024 | 70 | 0.210 |
Why?
|
| Esophageal Stenosis | 1 | 2024 | 46 | 0.210 |
Why?
|
| Salvage Therapy | 1 | 2025 | 177 | 0.200 |
Why?
|
| Pancreatic Ducts | 2 | 2022 | 20 | 0.200 |
Why?
|
| Rectal Neoplasms | 1 | 2024 | 78 | 0.200 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 75 | 0.200 |
Why?
|
| Glycosides | 1 | 2023 | 10 | 0.200 |
Why?
|
| Aftercare | 1 | 2024 | 153 | 0.200 |
Why?
|
| Neoplasm Metastasis | 1 | 2026 | 710 | 0.200 |
Why?
|
| Recurrence | 2 | 2021 | 1484 | 0.200 |
Why?
|
| Diet, High-Fat | 2 | 2022 | 264 | 0.190 |
Why?
|
| Mice | 6 | 2026 | 18394 | 0.190 |
Why?
|
| Calculi | 1 | 2022 | 15 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2026 | 1000 | 0.190 |
Why?
|
| Rectum | 1 | 2023 | 103 | 0.190 |
Why?
|
| Cost-Benefit Analysis | 1 | 2025 | 545 | 0.190 |
Why?
|
| Lithotripsy | 1 | 2022 | 29 | 0.190 |
Why?
|
| Postoperative Care | 1 | 2024 | 303 | 0.180 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2024 | 129 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 223 | 0.180 |
Why?
|
| Niacin | 1 | 2022 | 59 | 0.180 |
Why?
|
| Cell Movement | 1 | 2026 | 882 | 0.180 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2018 | 231 | 0.180 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 3851 | 0.180 |
Why?
|
| Endothelin-1 | 1 | 2021 | 40 | 0.180 |
Why?
|
| Cyst Fluid | 1 | 2021 | 6 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 2578 | 0.180 |
Why?
|
| Gastroscopy | 1 | 2022 | 98 | 0.180 |
Why?
|
| Pancreatitis, Acute Necrotizing | 1 | 2021 | 4 | 0.170 |
Why?
|
| Cell Line, Tumor | 2 | 2026 | 3703 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2024 | 379 | 0.170 |
Why?
|
| Proton Pump Inhibitors | 1 | 2024 | 279 | 0.170 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 1547 | 0.170 |
Why?
|
| Time Factors | 4 | 2020 | 6283 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 1082 | 0.170 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 252 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2022 | 162 | 0.170 |
Why?
|
| Follow-Up Studies | 5 | 2022 | 5287 | 0.160 |
Why?
|
| United States | 6 | 2025 | 11846 | 0.160 |
Why?
|
| Japan | 2 | 2018 | 177 | 0.160 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 117 | 0.160 |
Why?
|
| Inflammation Mediators | 1 | 2021 | 229 | 0.160 |
Why?
|
| Equipment Design | 2 | 2024 | 557 | 0.160 |
Why?
|
| Anemia | 1 | 2024 | 357 | 0.160 |
Why?
|
| Chronic Pain | 1 | 2022 | 165 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2025 | 761 | 0.160 |
Why?
|
| Bile Ducts | 1 | 2019 | 54 | 0.150 |
Why?
|
| Proteome | 1 | 2021 | 288 | 0.150 |
Why?
|
| Endoscopes | 1 | 2019 | 18 | 0.150 |
Why?
|
| Neurosurgical Procedures | 1 | 2021 | 317 | 0.150 |
Why?
|
| Fatigue | 1 | 2020 | 199 | 0.150 |
Why?
|
| RNA, Long Noncoding | 1 | 2021 | 232 | 0.150 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 225 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2025 | 1697 | 0.140 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 819 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 372 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 312 | 0.140 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2018 | 14 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2019 | 155 | 0.140 |
Why?
|
| Triglycerides | 1 | 2021 | 605 | 0.140 |
Why?
|
| DNA Methylation | 1 | 2024 | 1094 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2018 | 148 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2025 | 1060 | 0.140 |
Why?
|
| Cecum | 1 | 2017 | 26 | 0.130 |
Why?
|
| Ulcer | 1 | 2017 | 51 | 0.130 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2018 | 74 | 0.130 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 144 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1352 | 0.130 |
Why?
|
| Biomarkers | 3 | 2021 | 3422 | 0.130 |
Why?
|
| Diagnosis, Differential | 2 | 2025 | 1916 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 302 | 0.130 |
Why?
|
| Adolescent | 6 | 2021 | 21018 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 277 | 0.130 |
Why?
|
| Sildenafil Citrate | 1 | 2016 | 57 | 0.120 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 171 | 0.120 |
Why?
|
| Insulin | 1 | 2021 | 1152 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2021 | 683 | 0.120 |
Why?
|
| DNA Adducts | 1 | 2016 | 71 | 0.120 |
Why?
|
| Fanconi Anemia | 1 | 2016 | 48 | 0.120 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 2315 | 0.120 |
Why?
|
| Jaundice | 1 | 2016 | 27 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 113 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1260 | 0.110 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 234 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2022 | 729 | 0.110 |
Why?
|
| Cisplatin | 1 | 2016 | 286 | 0.110 |
Why?
|
| North America | 2 | 2025 | 260 | 0.110 |
Why?
|
| Research Design | 1 | 2018 | 718 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 719 | 0.110 |
Why?
|
| Lymph Nodes | 2 | 2018 | 364 | 0.100 |
Why?
|
| Prognosis | 1 | 2024 | 4962 | 0.100 |
Why?
|
| Survival Rate | 1 | 2019 | 2154 | 0.100 |
Why?
|
| Texas | 3 | 2017 | 3646 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 3003 | 0.100 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 1614 | 0.100 |
Why?
|
| Abdominal Pain | 1 | 2016 | 316 | 0.100 |
Why?
|
| Young Adult | 3 | 2018 | 10128 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2019 | 708 | 0.100 |
Why?
|
| DNA Repair | 1 | 2016 | 577 | 0.100 |
Why?
|
| Hemorrhage | 2 | 2023 | 500 | 0.090 |
Why?
|
| Cholecystectomy | 1 | 2012 | 57 | 0.090 |
Why?
|
| Inflammation | 3 | 2025 | 1503 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2014 | 1237 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2024 | 264 | 0.080 |
Why?
|
| Hospitalization | 2 | 2025 | 1944 | 0.080 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 228 | 0.080 |
Why?
|
| Enterotoxins | 1 | 1990 | 77 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2011 | 173 | 0.080 |
Why?
|
| Mass Screening | 1 | 2015 | 825 | 0.070 |
Why?
|
| Mercury Poisoning | 1 | 2009 | 6 | 0.070 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2009 | 82 | 0.070 |
Why?
|
| Bacterial Toxins | 1 | 1990 | 170 | 0.070 |
Why?
|
| Linear Models | 1 | 2011 | 696 | 0.070 |
Why?
|
| Mutagenesis, Insertional | 1 | 2009 | 152 | 0.070 |
Why?
|
| Inhalation Exposure | 1 | 2009 | 38 | 0.070 |
Why?
|
| Retinitis Pigmentosa | 1 | 2009 | 89 | 0.070 |
Why?
|
| Cesarean Section | 1 | 2012 | 436 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2021 | 15089 | 0.070 |
Why?
|
| Music Therapy | 1 | 2008 | 8 | 0.070 |
Why?
|
| Eye Proteins | 1 | 2009 | 239 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 1964 | 0.070 |
Why?
|
| Diarrhea | 1 | 1990 | 313 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 422 | 0.070 |
Why?
|
| Bacteroides Infections | 1 | 2007 | 2 | 0.070 |
Why?
|
| Escherichia coli Proteins | 1 | 1990 | 310 | 0.070 |
Why?
|
| Spondylitis | 1 | 2007 | 8 | 0.070 |
Why?
|
| Bacteroides fragilis | 1 | 2007 | 5 | 0.070 |
Why?
|
| Withholding Treatment | 1 | 2008 | 76 | 0.070 |
Why?
|
| Contrast Media | 1 | 2011 | 492 | 0.070 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2024 | 68 | 0.060 |
Why?
|
| Colitis | 1 | 2009 | 163 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2008 | 92 | 0.060 |
Why?
|
| Warfarin | 1 | 2008 | 123 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2012 | 555 | 0.060 |
Why?
|
| Lumbar Vertebrae | 1 | 2007 | 108 | 0.060 |
Why?
|
| Longitudinal Studies | 2 | 2022 | 1525 | 0.060 |
Why?
|
| Child | 5 | 2021 | 26361 | 0.060 |
Why?
|
| Infant | 3 | 2018 | 13343 | 0.060 |
Why?
|
| Esophageal Spasm, Diffuse | 1 | 2025 | 3 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2025 | 50 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2018 | 8613 | 0.050 |
Why?
|
| Lipid Peroxidation | 1 | 2024 | 91 | 0.050 |
Why?
|
| Escherichia coli | 1 | 1990 | 983 | 0.050 |
Why?
|
| Anal Canal | 1 | 2024 | 86 | 0.050 |
Why?
|
| Albumins | 1 | 2024 | 90 | 0.050 |
Why?
|
| Pancreatic Hormones | 1 | 2023 | 5 | 0.050 |
Why?
|
| Alkenes | 1 | 2023 | 8 | 0.050 |
Why?
|
| Injections, Intralesional | 1 | 2023 | 46 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2008 | 599 | 0.050 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 46 | 0.050 |
Why?
|
| Matrix Metalloproteinase 14 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Disaccharides | 1 | 2022 | 19 | 0.050 |
Why?
|
| Vinca Alkaloids | 1 | 2022 | 2 | 0.050 |
Why?
|
| Hydrolyzable Tannins | 1 | 2022 | 4 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 307 | 0.050 |
Why?
|
| Acetylcholinesterase | 1 | 2022 | 15 | 0.050 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2022 | 59 | 0.050 |
Why?
|
| Mutation | 1 | 2016 | 6197 | 0.050 |
Why?
|
| Vitamin E | 1 | 2022 | 63 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2025 | 520 | 0.050 |
Why?
|
| Manganese | 1 | 2022 | 59 | 0.050 |
Why?
|
| Neuroprotection | 1 | 2022 | 33 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2022 | 300 | 0.040 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2022 | 157 | 0.040 |
Why?
|
| Saudi Arabia | 1 | 2021 | 43 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2024 | 469 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 88 | 0.040 |
Why?
|
| Vinblastine | 1 | 2021 | 55 | 0.040 |
Why?
|
| Bleomycin | 1 | 2021 | 119 | 0.040 |
Why?
|
| Dacarbazine | 1 | 2021 | 94 | 0.040 |
Why?
|
| Fibrosis | 1 | 2023 | 421 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2022 | 328 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2025 | 797 | 0.040 |
Why?
|
| Models, Animal | 1 | 2023 | 460 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2022 | 236 | 0.040 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2021 | 69 | 0.040 |
Why?
|
| Peptides | 1 | 2024 | 725 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 406 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2020 | 36 | 0.040 |
Why?
|
| Manometry | 1 | 2020 | 73 | 0.040 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 293 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 222 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2021 | 301 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 329 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 335 | 0.040 |
Why?
|
| Pain | 1 | 2022 | 439 | 0.040 |
Why?
|
| Bile | 1 | 2019 | 44 | 0.040 |
Why?
|
| Drainage | 1 | 2021 | 253 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2022 | 1147 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 7588 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 67 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 703 | 0.040 |
Why?
|
| Optical Fibers | 1 | 2019 | 17 | 0.040 |
Why?
|
| Lasers | 1 | 2019 | 114 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 644 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2024 | 725 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2019 | 53 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 386 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 471 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2023 | 512 | 0.040 |
Why?
|
| Blood Specimen Collection | 1 | 2018 | 46 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 99 | 0.040 |
Why?
|
| Disease Progression | 2 | 2018 | 2229 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 126 | 0.030 |
Why?
|
| Smoking | 1 | 2023 | 929 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2023 | 4696 | 0.030 |
Why?
|
| Cohort Studies | 2 | 2022 | 5124 | 0.030 |
Why?
|
| Esophagus | 1 | 2019 | 238 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 85 | 0.030 |
Why?
|
| Resuscitation | 1 | 2019 | 280 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 240 | 0.030 |
Why?
|
| Necrosis | 1 | 2016 | 195 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 431 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 599 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 4071 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1625 | 0.020 |
Why?
|
| DNA Damage | 1 | 2016 | 527 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 4691 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3358 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 894 | 0.020 |
Why?
|
| Malaysia | 1 | 1990 | 17 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1990 | 52 | 0.020 |
Why?
|
| Sensory Thresholds | 1 | 2009 | 32 | 0.020 |
Why?
|
| Dark Adaptation | 1 | 2009 | 33 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 1990 | 86 | 0.020 |
Why?
|
| Electroretinography | 1 | 2009 | 107 | 0.020 |
Why?
|
| Refractive Errors | 1 | 2009 | 59 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2868 | 0.020 |
Why?
|
| Visual Fields | 1 | 2009 | 141 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 631 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 82 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 769 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2008 | 170 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 356 | 0.020 |
Why?
|
| Metronidazole | 1 | 2007 | 161 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2009 | 535 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2008 | 358 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2008 | 460 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 265 | 0.010 |
Why?
|